NAMPT Inhibitor FK866 as a Potent Molecule to Promote DrugSensitivity to Temozolomide in Glioma Cell

• 作 者: 王培银[1]李明眏[2]周文科[1]金保哲[1]张晨光[3]江涛[4]张新中[1]丁卫[5]
• 机 构: Department of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang M
• 出 处: 中国生物化学与分子生物学会第十一次会员代表大会暨2014年全国学术会议
• 发表日期: 2014年期

　　Glioma is a primary brain tumor with most prevalence and poor prognosis.Temozolomide(TMZ) is the firstline chemotherapy drug to treat glioma patients post surgery.However, the failure of chemotherapy is often seen due to the development of tumorcell resistance to the cytotoxic effects of TMZ.